<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-2094</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МНЕНИЕ ПО ПРОБЛЕМЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OPINION ON A PROBLEM</subject></subj-group></article-categories><title-group><article-title>Взаимодействие альтернативной терапии с варфарином: что необходимо знать врачам</article-title><trans-title-group xml:lang="en"><trans-title>Alternative therapy interaction with warfarin: what doctors should know</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козлова</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kozlova</surname><given-names>T. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доцент кафедры госпитальной терапии № 1</p></bio><email xlink:type="simple">dockozlova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Таратута</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Taratuta</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ассистент кафедры общей врачебной практики</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аксенова</surname><given-names>М. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Aksenova</surname><given-names>M. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доцент кафедры госпитальной терапии № 1</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хлевчук</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Khlevchuk</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доцент кафедры госпитальной терапии № 1</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Московская медицинская академия им. И. М. Сеченова. Москва<country>Россия</country></aff><aff xml:lang="en">I.M. Sechenov Moscow Medical Academy. Moscow<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>20</day><month>06</month><year>2010</year></pub-date><volume>9</volume><issue>3</issue><fpage>106</fpage><lpage>110</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Козлова Т.В., Таратута Т.В., Аксенова М.Б., Хлевчук Т.В., 2010</copyright-statement><copyright-year>2010</copyright-year><copyright-holder xml:lang="ru">Козлова Т.В., Таратута Т.В., Аксенова М.Б., Хлевчук Т.В.</copyright-holder><copyright-holder xml:lang="en">Kozlova T.B., Taratuta T.V., Aksenova M.B., Khlevchuk T.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/2094">https://cardiovascular.elpub.ru/jour/article/view/2094</self-uri><abstract><p>Варфарин представляет собой лекарственный препарат, на эффективность и безопасность которого значительно влияет сопутствующая терапия. В статье рассмотрены основные механизмы лекарственного взаимодействия с варфарином, лежащие в основе нежелательных реакций: нарушение функции тромбоцитов, повреждение желудочно-кишечного тракта, подавление синтеза витамина К в кишечнике, нарушение метаболизма варфарина, вмешательство в цикл витамина К. Выделены основные группы препаратов, которые воздействуют на варфарин. В статье отмечено разнонаправленное влияние пищевых продуктов, биологически активных добавок, растительных препаратов на гипокоагулянтный эффект варфарина.</p></abstract><trans-abstract xml:lang="en"><p>Warfarin effectiveness and safety is substantially affected by concurrent therapy. This paper reviews the main mechanisms of warfarin interactions with other agents, which underlie adverse effect development: platelet dysfunction, gastro-intestinal effects, suppressed intestinal synthesis of vitamin K, disturbed warfarin metabolism, or disrupted vitamin K cycle. The main medication groups, affecting warfarin effectiveness and safety, are presented. The effects of foods, supplements, and herbal medications on anticoagulant effect of warfarin are discussed.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>варфарин</kwd><kwd>сопутствующая терапия</kwd><kwd>взаимодействие с пищевыми и растительными продуктами</kwd><kwd>контроль МНО</kwd></kwd-group><kwd-group xml:lang="en"><kwd>warfarin</kwd><kwd>concurrent therapy</kwd><kwd>interaction with foods and herbal medications</kwd><kwd>INR control</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Anthony M, Romero K, Malone DC, et al. Warfarin Interactions With Substances Listed in Drug Information Compendia and in the FDA-Approved Label for Warfarin Sodium. Clin pharmacy Ther 2009; 86: 425—9.</mixed-citation><mixed-citation xml:lang="en">Anthony M, Romero K, Malone DC, et al. Warfarin Interactions With Substances Listed in Drug Information Compendia and in the FDA-Approved Label for Warfarin Sodium. Clin pharmacy Ther 2009; 86: 425—9.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Chagan L, Bernstein D, Cheng JW, et al. Use of biological based therapy in patients with cardiovascular diseases in a universityhospital in New York City. BMC Complement Altern Med 2005; 5: 4—13.</mixed-citation><mixed-citation xml:lang="en">Chagan L, Bernstein D, Cheng JW, et al. Use of biological based therapy in patients with cardiovascular diseases in a universityhospital in New York City. BMC Complement Altern Med 2005; 5: 4—13.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Conly JM, Stein K, Worobetz L, et al. The contribution of vitamin K2 (menaquinones) produced by the intestinal microflora to human nutritional requirements for vitamin K. Am J Gastroenterol 1994; 89: 915—23.</mixed-citation><mixed-citation xml:lang="en">Conly JM, Stein K, Worobetz L, et al. The contribution of vitamin K2 (menaquinones) produced by the intestinal microflora to human nutritional requirements for vitamin K. Am J Gastroenterol 1994; 89: 915—23.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990—1997: results of a follow-up national survey. JAMA 1998; 280: 1569—75.</mixed-citation><mixed-citation xml:lang="en">Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990—1997: results of a follow-up national survey. JAMA 1998; 280: 1569—75.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 2007; 23: 134—41.</mixed-citation><mixed-citation xml:lang="en">Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 2007; 23: 134—41.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Foti RS, Wahlstrom JL, Wienkers LC. The in vitro drug interaction potential of dietary supplements containing multiple herbal components. Drug Metab Disp 2007; 35: 185—8.</mixed-citation><mixed-citation xml:lang="en">Foti RS, Wahlstrom JL, Wienkers LC. The in vitro drug interaction potential of dietary supplements containing multiple herbal components. Drug Metab Disp 2007; 35: 185—8.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 2005; 45: 127—32.</mixed-citation><mixed-citation xml:lang="en">Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 2005; 45: 127—32.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095—106.</mixed-citation><mixed-citation xml:lang="en">Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095—106.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs 2005; 65(9): 1239—82.</mixed-citation><mixed-citation xml:lang="en">Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs 2005; 65(9): 1239—82.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Joshi BS, Kaul PN. Alternative medicine: herbal drugs and their critical appraisal—part I. Prog Drug Res 2001; 56: 1—76.</mixed-citation><mixed-citation xml:lang="en">Joshi BS, Kaul PN. Alternative medicine: herbal drugs and their critical appraisal—part I. Prog Drug Res 2001; 56: 1—76.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lumb AB. Effect of dried ginger on human platelet function. Thromb Haemost 1994; 71: 110—1.</mixed-citation><mixed-citation xml:lang="en">Lumb AB. Effect of dried ginger on human platelet function. Thromb Haemost 1994; 71: 110—1.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004; 91: 119—28.</mixed-citation><mixed-citation xml:lang="en">Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004; 91: 119—28.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Newall CA, Anderson LA, Phillipson JD. Herbal medicines: a guide for health-care professionals. London: Pharmaceutical Press 1996.</mixed-citation><mixed-citation xml:lang="en">Newall CA, Anderson LA, Phillipson JD. Herbal medicines: a guide for health-care professionals. London: Pharmaceutical Press 1996.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Nutescu EA, Shapiro NL, Ibrahim S, et al. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 2006; 5: 433—51.</mixed-citation><mixed-citation xml:lang="en">Nutescu EA, Shapiro NL, Ibrahim S, et al. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 2006; 5: 433—51.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Stading JA, Skrabal MZ, Faulkner MA. Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors. Am J Health Syst Pharm 2001; 58: 2076—80.</mixed-citation><mixed-citation xml:lang="en">Stading JA, Skrabal MZ, Faulkner MA. Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors. Am J Health Syst Pharm 2001; 58: 2076—80.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Sullivan DM, Ford MA, Boyden TW. Grapefruit juice and the response to warfarin. Am J Health Syst Pharm 1998; 55: 1581—3.</mixed-citation><mixed-citation xml:lang="en">Sullivan DM, Ford MA, Boyden TW. Grapefruit juice and the response to warfarin. Am J Health Syst Pharm 1998; 55: 1581—3.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40: 587—603.</mixed-citation><mixed-citation xml:lang="en">Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40: 587—603.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Thijssen HH, Soute BA, Vervoort LM, et al. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb Haemost 2004; 92: 797—802.</mixed-citation><mixed-citation xml:lang="en">Thijssen HH, Soute BA, Vervoort LM, et al. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb Haemost 2004; 92: 797—802.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Wittkowsky Ann K. Dietary supplements, herbs and oral anticoagulants: the nature of the evidence. J Thromb Thrombolysis 2008; 25: 72—7.</mixed-citation><mixed-citation xml:lang="en">Wittkowsky Ann K. Dietary supplements, herbs and oral anticoagulants: the nature of the evidence. J Thromb Thrombolysis 2008; 25: 72—7.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Wood MJ, Stewart RL, Merry H, et al. Use of complementary and alternative medical therapies in patients with cardiovascular disease. Am Heart J 2003; 145: 806—12.</mixed-citation><mixed-citation xml:lang="en">Wood MJ, Stewart RL, Merry H, et al. Use of complementary and alternative medical therapies in patients with cardiovascular disease. Am Heart J 2003; 145: 806—12.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Zhaoping LI, Seerman NP, Carpenter CL, et al. Cranberry does not affect prothrombin time in male subjects on warfarin. J Am Diet Assoc 2006; 106: 2057—61.</mixed-citation><mixed-citation xml:lang="en">Zhaoping LI, Seerman NP, Carpenter CL, et al. Cranberry does not affect prothrombin time in male subjects on warfarin. J Am Diet Assoc 2006; 106: 2057—61.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
